TY - JOUR
T1 - Emerging biomarkers for the combination of radiotherapy and immune checkpoint blockers
AU - Lhuillier, Claire
AU - Vanpouille-Box, Claire
AU - Galluzzi, Lorenzo
AU - Formenti, Silvia Chiara
AU - Demaria, Sandra
N1 - Publisher Copyright:
© 2017 Elsevier Ltd
PY - 2018/10
Y1 - 2018/10
N2 - Over the past few years, multiple immune checkpoint blockers (ICBs) have achieved unprecedented clinical success and have been approved by regulatory agencies for the treatment of an increasing number of malignancies. However, only a limited fraction of patients responds to ICBs employed as a standalone intervention, calling for the development of combinatorial regimens. Radiation therapy (RT) stands out as a very promising candidate for this purpose. Indeed, RT mediates antineoplastic effects not only by cytotoxic and cytostatic mechanisms, but also by modulating immunological functions, both locally (within the irradiated field) and systemically. As combinatorial regimens involving RT and ICBs are being developed and clinically tested at an accelerating pace, it is paramount to identify biomarkers that reliably predict the likelihood of individual patients to respond. Here, we discuss emerging biomarkers that may potentially predict the response of cancer patients to RT plus ICBs.
AB - Over the past few years, multiple immune checkpoint blockers (ICBs) have achieved unprecedented clinical success and have been approved by regulatory agencies for the treatment of an increasing number of malignancies. However, only a limited fraction of patients responds to ICBs employed as a standalone intervention, calling for the development of combinatorial regimens. Radiation therapy (RT) stands out as a very promising candidate for this purpose. Indeed, RT mediates antineoplastic effects not only by cytotoxic and cytostatic mechanisms, but also by modulating immunological functions, both locally (within the irradiated field) and systemically. As combinatorial regimens involving RT and ICBs are being developed and clinically tested at an accelerating pace, it is paramount to identify biomarkers that reliably predict the likelihood of individual patients to respond. Here, we discuss emerging biomarkers that may potentially predict the response of cancer patients to RT plus ICBs.
KW - DNA damage response
KW - Mutational load
KW - Natural killer cells
KW - PD-L1
KW - Type I interferon
UR - http://www.scopus.com/inward/record.url?scp=85039044992&partnerID=8YFLogxK
U2 - 10.1016/j.semcancer.2017.12.007
DO - 10.1016/j.semcancer.2017.12.007
M3 - Review article
C2 - 29258856
AN - SCOPUS:85039044992
SN - 1044-579X
VL - 52
SP - 125
EP - 134
JO - Seminars in Cancer Biology
JF - Seminars in Cancer Biology
ER -